How to be a contrarian investor – and why!
Human beings are not evolutionarily well adapted to be good at investing. But there are some basic principles that will stack the odds firmly in your favour, writes fund manager Tim Price.
Human beings are not evolutionarily well adapted to be good at investing. But there are some basic principles that will stack the odds firmly in your favour, writes fund manager Tim Price.
Bloomsbury Publishing is due to announce a trading update soon – and Mark Watson-Mitchell thinks it work could work magic for the shares.
Robert Stephens focuses on the long-term appeal of two real estate investment trusts – Workspace and Great Portland Estates.
Shares in Manolete have soared following a very positive trading update – but there could be more to come, writes Mark Watson-Mitchell.
PCF Group has the capability to increase its lending portfolio quite significantly – from the £350m target by end September 2020 to £750m by 2022, writes Mark Watson-Mitchell.
The March results for this refunded music IP group should show a very positive outlook, writes small-cap guru Mark Watson-Mitchell.
Robert Stephens, CFA, considers the outlook for two heavyweight British pharmaceutical stocks.
Property management specialist HML Holdings is seriously undervalued at up to 50p per share, argues Mark Watson-Mitchell.
Shares in FairFX could well be worth tucking away, especially if we can get Brexit over and done with, argues Mark Watson-Mitchell.
Manolete Partners is widely recognised as the leading insolvency financing company and it’s on the radar of small-cap guru Mark Watson-Mitchell.